AbbVie Inc. (ABBV) Stock Analysis
Last updated Sep 8, 2026
Published Opportunity
This stock was published as a Compound Radar opportunity on Jul 17, 2026. Performance is tracked publicly from the original signal.
Health Check
Last analyzed Sep 7, 2026
- Financial Health 65
- Profitability 75
- Business Quality 100
- Balance Sheet 55
- Cash Flow 45
Why this rating?
Health 73/100 — High Quality
Worth tracking, but timing is mixed — not a clear setup yet.
Company overview
AbbVie Inc. (ABBV) is a Drug Manufacturers - General company in the Healthcare sector. Compound Radar rates AbbVie Inc. 73/100 (High Quality) due to high business quality, steady revenue growth, and manageable leverage.
Investment profile
- Quality High
- Growth Moderate
- Balance Sheet Adequate
- Valuation Attractive
Financial highlights
Valuation
- P/E 70.28
- Forward P/E 15.28
- PEG 0.36
- EV/Revenue 8.04
Profitability
- Revenue Growth 10.2%
- Gross Margin 72.8%
- Operating Margin 40.0%
- Net Margin 9.8%
Financial strength
- Cash $6.57B
- Debt $70.88B
- Net Cash $-64.32B
- Free Cash Flow $17.82B
- Current Ratio 0.81
Similar companies
Peers in Drug Manufacturers - General, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Eli Lilly and Company Drug Manufacturers - General LLY$1,123.91 86 Health 86 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- AstraZeneca PLC Drug Manufacturers - General AZN$160.04 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Gilead Sciences, Inc. Drug Manufacturers - General GILD$146.64 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Biogen Inc. Drug Manufacturers - General BIIB$212.50 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Bristol-Myers Squibb Company Drug Manufacturers - General BMY$64.69 72 Health 72 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Johnson & Johnson Drug Manufacturers - General JNJ$269.12 71 Health 71 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Pfizer Inc. Drug Manufacturers - General PFE$27.79 71 Health 71 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Amgen Inc. Drug Manufacturers - General AMGN$393.17 68 Health 68 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks AbbVie Inc. (ABBV).